arrow
Y

Yin-Hsun Feng

chi mei hospital
H指数:25
被引数:3,437

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to Comment on “Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort”

对“改良FOLFIRINOX在胰管腺癌中的最佳初始相对剂量强度:一项回顾性多中心队列研究”的评论回复

2026-05-050
OAAI
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

改良FOLFIRINOX在胰管腺癌中的最佳初始相对剂量强度:一项回顾性多中心队列研究

2026-04-120
OAAI
Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor
2024-04-051
PRE
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study
CANCER
IF5.1
2021-08-208
OAAI
IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
2021-07-0115
PRE
CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane
2020-02-150
PRE